Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells

Identification of mechanisms underlying sensitivity and response to targeted therapies, such as the BRAF inhibitor vemurafenib, is critical in order to improve efficacy of these therapies in the clinic and delay onset of resistance. Glycolysis has emerged as a key feature of the BRAF inhibitor respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Lorey K., Parmenter, Tiffany, Gould, Cathryn M., Madhamshettiwar, Piyush B., Sheppard, Karen E., Simpson, Kaylene J., McArthur, Grant A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Data Descriptor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550327/
https://www.ncbi.nlm.nih.gov/pubmed/33046726
http://dx.doi.org/10.1038/s41597-020-00683-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550327/
https://www.ncbi.nlm.nih.gov/pubmed/33046726
http://dx.doi.org/10.1038/s41597-020-00683-z

Ejemplares similares